Atopic Dermatitis
Conditions
Keywords
Upadacitinib, ABT-494, Atopic Dermatitis, RINVOQ
Brief summary
The objective of this study is to evaluate the safety, pharmacokinetics and tolerability of multiple doses of upadacitinib in pediatric participants with severe atopic dermatitis and to evaluate palatability of upadacitinib oral solution in pediatric participants.
Interventions
Upadacitinib will be administered orally.
Sponsors
AbbVie
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 12 Years
Healthy volunteers
No
Inclusion criteria
* Participants with total body weight of 10 kilograms(kg) or higher at Baseline. Beginning with protocol version 6.0, only subjects 3 years of age and older will be enrolled for the remainder of this study. * Diagnosed with atopic dermatitis (AD) with onset of symptoms at least 6 months prior to baseline. * Meets Hanifin and Rajka criteria for AD. * Diagnosed with active severe AD defined by Eczema Area Severity Index (EASI), Validated Investigator's Global Assessment (IGA) and body surface area (BSA). * Documented history (within 12 months prior to the Baseline Visit) of inadequate response or intolerance to topical corticosteroids (TCS) and topical calcineurin inhibitor (TCI) OR for whom use of TCS and TCIs is otherwise medically inadvisable.
Exclusion criteria
* Prior exposure to Janus Kinase (JAK) inhibitor. * Requirement of prohibited medications during the study. * Current use of known moderate or strong inhibitors or inducers of drug metabolizing enzymes within 30 days prior to the first dose of study drug and through the end of Part 1 of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Plasma Concentration (Cmax) | Up to 7 days | It is defined as the maximum observed plasma concentration (Cmax) for upadacitinib. |
| Time to Maximum Observed Plasma Concentration (Tmax) | Up to 7 days | It is defined as the time to maximum plasma concentration (Tmax) of upadacitinib. |
| Area under the plasma concentration-time curve within a dosing interval (AUCtau) | Up to 7 days | The area under the plasma concentration-time curve (AUCtau) is a method of measurement of the total exposure of a drug in plasma. |
| Oral Clearance | Up to 7 days | Clearance is defined the volume of plasma cleared of the drug per unit time. |
| Number of Participants With Treatment Emergent Adverse Events (TEAE) | Up to 2 years | An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events (TEAEs) are defined as any event that began or worsened in severity after the first dose of study drug. |
Countries
Norway, Puerto Rico, United States
Outcome results
None listed